# Gemcitabine With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

> **NCT00088894** · PHASE3 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 590 (actual)

## Conditions studied

- Adenocarcinoma of the Pancreas
- Recurrent Pancreatic Cancer
- Stage II Pancreatic Cancer
- Stage III Pancreatic Cancer
- Stage IV Pancreatic Cancer

## Interventions

- **DRUG:** gemcitabine hydrochloride
- **BIOLOGICAL:** bevacizumab
- **OTHER:** placebo
- **OTHER:** laboratory biomarker analysis
- **OTHER:** pharmacogenomic studies
- **OTHER:** pharmacological study

## Key facts

- **NCT ID:** NCT00088894
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-06
- **Primary completion:** 2006-06
- **Final completion:** —
- **Target enrollment:** 590 (ACTUAL)
- **Last updated:** 2013-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00088894

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00088894, "Gemcitabine With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00088894. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*